AI illustration · not actual product photoDetails from the source.
Source-listed CJC-1295 With DAC (SKU CD5): 5mg*10vials. PriceList(1).pdf lists 157 per 10 vials but does not specify currency; the website displays $157 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- CD5
- Source specification
- 5mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The catalogue names CJC-1295 With DAC, a synthetic modified peptide/GHRH analogue in scientific literature. The source label is preserved. Research on the named molecule does not verify the composition, DAC modification, salt, purity, or formulation of the supplier-specific CD2/CD5 vials.
Biological mechanism
Preclinical cell and rat work found GHRH-receptor activity and extended circulation through association with serum albumin. In a small human study, CJC-1295 produced prolonged increases in circulating growth hormone (GH) and IGF-I. The albumin-binding/receptor mechanism evidence is not proof that these catalogue vials contain the studied molecule. [1] [2]
Research focus
Human research has examined pharmacokinetics, safety, and sustained GH/IGF-I responses in healthy adults. Preclinical studies examined receptor activity and albumin bioconjugation. Evidence concerns endocrine biomarkers, not established clinical benefit. [1] [2]
Potential applications in the evidence
Investigated for sustained stimulation of the GH–IGF-I axis. The available evidence does not establish an effective or approved treatment for growth hormone deficiency, body composition, athletic performance, aging, or another condition. [1]
Human evidence
A 2006 pair of randomized, placebo-controlled, ascending-dose studies in healthy adults found dose-related GH increases for at least six days and IGF-I increases for 9–11 days after a single study administration; estimated half-life was 5.8–8.1 days. With multiple study administrations, mean IGF-I remained above baseline for up to 28 days. No serious adverse reactions were reported in those trials. They measured hormone and pharmacokinetic outcomes, not lasting patient-important benefits, and do not establish long-term safety. [1]
Known and potential effects
The human trials reported sustained increases in GH and IGF-I and no serious adverse reactions during the limited studies. FDA’s compounding-safety review separately identifies serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction. FDA also notes potential immunogenicity for certain administration routes, possible peptide-related impurities/API-characterization complexity, and limited clinical data. These findings do not establish the contents or risk profile of the listed vials. [1] [3]
Safety and contraindications
Sustained GH/IGF-I changes and FDA-identified serious adverse-event reports warrant caution; short trials cannot establish safety for prolonged exposure or people with conditions affected by this hormone pathway. The reviewed sources do not establish a complete contraindication list for the exact catalogue item. FDA’s concerns about immunogenicity and peptide-related impurities apply to CJC-1295-related substances in compounding contexts and cannot be used to determine the quality or composition of these specific vials. No safety guarantee or human-use instructions can be inferred. [1] [3]
U.S. FDA / regulatory status
The reviewed sources provide no evidence of an FDA-approved CJC-1295 drug or an FDA-approved branded formulation corresponding to CD2/CD5; that is not a verified determination for a supplier-specific vial. FDA lists CJC-1295 in the “nominated but withdrawn” section of its bulk-substance safety page and retains concerns about adverse events, immunogenicity, impurities, and limited clinical data. This is not an approval and does not prove these vials are compounded. FDA’s 503A page describes conditions for certain pharmacy-compounded drugs but does not establish that these vials meet them. The provided material does not establish that the item is compounded or research-only. [3] [4] [5]
Evidence limitations
Human evidence is sparse and largely limited to short-term endocrine/pharmacokinetic outcomes in healthy adults. Preclinical cell and animal findings should not be presented as human outcomes. The supplied catalogue does not identify manufacturer, lot, API source, formulation, jurisdiction, or an approval; no identity, quality, dose content, sterility, or stability claims for the exact vials can be verified. The PDF lists CD2 as *10vials at 76 per 10 vials and CD5 as *10vials at 157 per 10 vials; currency is not stated. [1] [2]
Supporting sources
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults National Library of Medicine (PubMed) · Primary human randomized, placebo-controlled clinical trial record. Supports: Human pharmacokinetics, GH/IGF-I biomarker changes, study design and duration, and no serious adverse reactions reported in the trials.
- Human growth hormone-releasing factor albumin bioconjugates activate the GRF receptor in rats National Library of Medicine (PubMed) · Primary preclinical study; cell and rat experiments. Supports: Preclinical GHRH/GRF receptor activity, albumin association, and extended persistence; supports clearly separating animal/cell findings from human evidence.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Official FDA safety information. Supports: FDA’s CJC-1295-related concerns about serious adverse events, immunogenicity for certain routes, peptide-related impurities/API characterization, limited clinical data, and the withdrawn-nomination listing.
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration · Official FDA compounding policy and listing page. Supports: Explains the regulatory requirements and categories for bulk drug substances used in certain 503A compounding; does not establish the status of these supplier vials.
- Understanding the Risks of Compounded Drugs U.S. Food and Drug Administration · Official FDA consumer safety information. Supports: Explains that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing; cited conditionally because the catalogue does not establish that this item is compounded.